Abuse potential of sibutramine [3];Potencial de abuso de sibutramina

Medicina Clinica

Volumn 120, Issue 16, 2003, Pages 639-

  Saiz Ruiz, Jerónimo ^a   Saiz González, Dolores ^b   Fructuoso, Pedro Antón ^c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Clinica Mediterranea de Neurociencias   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINEPTINE; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; DEXAMPHETAMINE; METFORMIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; LETTER; OBESITY;

EID: 0038174778     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13046923     Document Type: Letter

References (8)

1. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
2. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabet Obes Metab 2002;4:49-55.
3. Pereira JL, López-Pardo F, Parejo J, Astorga R, Rodríguez-Puras MJ, García-Luna PP. Estudio de la función valvular cardíaca en pacientes obesos tratados con sibutramina. Med Clin (Barc) 2002; 118:57-9.
4. Schuh LM, Schuster CR, Hopper JA, Mendel CM. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 2000;147:339-46.
5. Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, et al. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 2000;38:167-76.
6. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22(Supl 1):18-28.
7. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998; 18:231-6.
8. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.